Clinical Trials Directory

Trials / Sponsors / Immutep S.A.S.

Immutep S.A.S.

Industry · 11 registered clinical trials — 1 currently recruiting.

StatusTrialPhaseStarted
Active Not RecruitingStudy of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combinat
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 32025-03-21
RecruitingA First-in-human Study of the Safety of an Immunosuppressive Antibody (IMP761) in Healthy Volunteers
Healthy
Phase 12024-07-17
WithdrawnA Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP3
Metastatic Breast Cancer
Phase 12023-06-01
Active Not RecruitingStudy in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitax
Breast Carcinoma
Phase 2 / Phase 32023-05-22
CompletedCombination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With R
HNSCC
Phase 22021-08-27
CompletedCombination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients W
NSCLC, HNSCC
Phase 22019-02-18
CompletedIMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma
Adenocarcinoma Breast Stage IV
Phase 22015-12-01
CompletedIMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma
Metastatic Breast Cancer
Phase 12006-07-01
CompletedIMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)
Stage IV Renal Cell Carcinoma
Phase 12005-09-01
CompletedA Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321
Healthy
Phase 12005-05-01
CompletedPhase I Study of IMP321 Given Alone or as an Adjuvant to a Reference Flu Antigen
Healthy
Phase 12005-04-01